John Oyler on cancer
From BeOneMedicines CEO John V Oyler on the state of biotech, modalities, and SF vs London. · · BiotechTV
“The progress we're making with science, especially in targeted therapies like ADCs and T-cell engagers, is crazy and has the potential to revolutionize cancer treatment.”
On , John Oyler, Former CEO at BeiGene, spoke about cancer during BeOneMedicines CEO John V Oyler on the state of biotech, modalities, and SF vs London. on BiotechTV.
About John Oyler
John Oyler, former CEO of BeiGene and now CEO of BeOneMedicines, has been discussing the state of the biotech industry and his company's strategic focus. In a November 2025 interview, Oyler expressed a positive outlook for biotech, citing significant scientific breakthroughs in modalities such as ADCs, bispecific antibodies, and T-cell engagers. He noted that there remains unmet medical need in oncology, with 10 million cancer deaths annually, and described the progress in science as "crazy" with potential for huge impact. Oyler also discussed the future of antibody therapies, stating that while there is still space for unarmed antibodies, much focus is on more customized approaches, including conjugating antibodies with degraders to target tissues precisely. In earlier interviews from 2024, Oyler detailed BeiGene's strategy of building internal capabilities in manufacturing and clinical development, including a focus on protein degradation and biologics manufacturing. He emphasized the company's approach to board transparency, sharing the "worst things we're worried about" rather than just successes. Oyler also discussed the impact of China's evolving regulatory system and reimbursement of innovative medicines, stating that including China in clinical trials could change fundamental economics and make drugs more affordable globally. He described BeiGene's aspiration to be a "lasting major global player" and a "global leader from China."
This quote was transcribed and extracted with AI assistance from a verified, first-person interview, then reviewed by our team to confirm the speaker and the exact wording. See how we verify →